| Registry | NCT05807022 |
|---|---|
| Status | Unknown |
| Phase | Not applicable |
| Study type | Interventional; na, single group, masking: none, treatment |
| Enrollment | 60 (Estimated) |
| Sponsor | China-Japan Friendship Hospital (Other) |
| Conditions | Lung Cancer |
| Interventions | Percutaneous or transbronchial argon-helium cryoablation (Procedure) |
| Dates | start 2023-03-30 (estimated), primary completion 2024-12-01 (estimated), completion 2024-12-31 (estimated), first posted 2023-04-10, last updated 2023-04-10 |
Related Papers Related Patents Related Grants Related Experts
All trials for Lung Cancer All trials of Percutaneous or transbronchial argon-helium cryoablation
The goal clinical trial is to evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation in primary lung cancer and metastatic lung cancer. The main question it aims to answer are:Evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation.
Participants will undergo percutaneous or transbronchial argon-helium cryoablation.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Percutaneous or transbronchial argon-helium cryoablation | Experimental | Procedure: Percutaneous or transbronchial argon-helium cryoablation |
Sex: All, ages: 18 Years to 90 Years
Inclusion Criteria: * Primary or metastatic lung cancer with definite pathological diagnosis * Not suitable for thoracotomy due to serious or serious lung or systemic diseases * Peripheral lung cancer involves pleura and chest wall, and cannot be completely removed after surgery * There are indications for surgical resection, but the patient refuses to operate * Single tumor, maximum diameter ≤ 5cm * Or the number of tumors ≤ 3 and the maximum diameter ≤ 3cm * ECOG-PS score ≤ 2 * The expected survival period is more than three months * Those who have not participated in other clinical verifications within 3 months * Subjects voluntarily signed the informed consent form Exclusion Criteria: * Serious cardio-cerebral disease or other mental diseases * Severe pulmonary fibrosis, especially drug-induced pulmonary fibrosis * Patients with previous severe pulmonary dysfunction, pulmonary ventilation disorder and multiple pulmonary bullae * Have a history of immunodeficiency, including HIV test (enzyme-linked immunosorbent assay and Western blotting) positive * Chemotherapy, radiotherapy, interventional therapy, ablation and surgical treatment within 30 days before surgical treatment * There is a tendency to severe bleeding, and the platelet is less than 50 × 109/L and severe disorder of coagulation function * Coagulation index (PT, TT, APTT)>2.5 times of the upper normal limit * Malignant pleural effusion on the same side of the ablation focus was not well controlled * Poor general condition, multiple organ failure, cachexia, severe anemia and nutritional metabolism disorder * Those who have extensive extrapulmonary metastasis and are not suitable for ablation treatment * Those who often use sedatives, sleeping pills, tranquilizers or other addictive drugs * Pregnant or lactating women * Those who can not judge the curative effect * Other conditions determined by the researcher to be unsuitable for the group, such as inability to tolerate cryoablation, difficulty in follow-up, and other serious diseases